Updates in DLBCL Management—The Role of Antibody Drug Therapeutics in Frontline and Later-Line Management 
Pre-test

Questions marked with a * are required
100%
Contact Information
Which of the following statements regarding polatuzumab vedotin-based therapy is correct? 
Which of the following statements regarding polatuzumab vedotin-based therapy is correct? 
Marge, a 64-year-old female with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), is being evaluated for third-line therapy after her disease progression on front-line R-CHOP and second-line tafasitamab/lenalidomide. Her biopsy results are CD19–, CD20+, CD30+, CD3–, and CD10–. Fluorescence in situ hybridization testing reveals no rearrangement of MYC or BCL2. Which of the following treatment approaches is most directly informed by Marge’s molecular testing results?
Marge, a 64-year-old female with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), is being evaluated for third-line therapy after her disease progression on front-line R-CHOP and second-line tafasitamab/lenalidomide. Her biopsy results are CD19–, CD20+, CD30+, CD3–, and CD10–. Fluorescence in situ hybridization testing reveals no rearrangement of MYC or BCL2. Which of the following treatment approaches is most directly informed by Marge’s molecular testing results?
John is a 66-year-old male with relapsed/refractory CD20+, PAX5+, CD10+, MYC++ diffuse large B-cell lymphoma (DLBCL) and activated B-cell (ABC) subtype, whose disease progressed 4 years after initiating R-CHOP therapy. He subsequently received glofitamab + gemcitabine/oxaliplatin (GemOx). Now 18 months later his most recent positron emission tomography/computed tomography (PET/CT) scans indicate progressive disease. John lives in a rural area and lacks social support for overnight travel. Which treatment option below would be most appropriate for John at this stage of his disease? 
John is a 66-year-old male with relapsed/refractory CD20+, PAX5+, CD10+, MYC++ diffuse large B-cell lymphoma (DLBCL) and activated B-cell (ABC) subtype, whose disease progressed 4 years after initiating R-CHOP therapy. He subsequently received glofitamab + gemcitabine/oxaliplatin (GemOx). Now 18 months later his most recent positron emission tomography/computed tomography (PET/CT) scans indicate progressive disease. John lives in a rural area and lacks social support for overnight travel. Which treatment option below would be most appropriate for John at this stage of his disease? 
Which of the following toxicities is frequently associated with both bispecific antibody therapy and CAR-T therapy in the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) 
Which of the following toxicities is frequently associated with both bispecific antibody therapy and CAR-T therapy in the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) 
Powered by QuestionPro